Rapport Biomédicaments 2025 — 1ʳᵉ édition
MabDesign, en collaboration avec France Biotech, publie la première édition de son Rapport Biomédicaments : une analyse de référence dédiée à l’une des filières les plus stratégiques et innovantes de la santé.
Les biomédicaments, anticorps thérapeutiques, vaccins, thérapies cellulaires et thérapies géniques, représentent aujourd’hui le moteur de l’innovation thérapeutique mondiale. Ce rapport propose un panorama complet de leur dynamique de marché, de leur pipeline de développement et du positionnement de la France dans la compétition internationale
Les maladies inflammatoires chroniques de l’intestin
Les analyses de marché de MabDesign vous proposent chaque mois un aperçu des dynamiques du marché et des projets en développement pour une indication ou une technologie donnée, afin de mieux appréhender le marché en constante évolution des biomédicaments et de la bioproduction. Ce mois-ci, un aperçu du marché et des projets actuellement en développement pour le traitement des maladies inflammatoires chroniques de l’intestin (MICI).
chronic inflammatory bowel diseases
MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and projects currently under development for the treatment of inflammatory bowel diseases (IBD).
Human Immunodeficiency Virus
The MabDesign market analysis gives you an overview of market dynamics and projects currently in development for the prevention and treatment of Human Immunodeficiency Virus (HIV).
ADCs : antibodies and cytotoxic molecules united against tumours
From Paul Ehrlich’s early “magic bullet” concept to today’s approved therapeutics, Antibody-Drug Conjugates (ADCs) represent a major breakthrough in targeted cancer therapy. By combining the selectivity of monoclonal antibodies with the potency of cytotoxic agents, ADCs aim to eliminate tumor cells while sparing healthy tissues. This article dives into the evolution, design strategies, and key challenges of these complex biologics.
Bioproduction of viral vectors: challenges, innovations and market prospects
Viral vectors are essential therapeutic tools for gene therapy and certain vaccines. The growing number of cell and gene therapy products on the market means that the production of viral vectors is an increasingly strategic sector.
Biomanufacturing of biological drugs: strategic issues and challenges
Biomanufacturing, or the manufacturing phase of innovative biological medicines, is a rapidly expanding field that is essential for meeting modern healthcare needs and represents a major strategic challenge. Faced with growing dependence on imports and increasing international competition, there are many technological and industrial challenges to developing this sector. In France, major efforts are being made, notably through the France 2030 plan, to ensure pharmaceutical sovereignty and meet future medical needs. This article explores the challenges and opportunities presented by biomanufacturing.
The immuno-oncology market
Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
The beginnings of cell culture
Cell culture is the cornerstone of biomedical research and biotechnology innovation. Although the bioproduction of biomedicines in bioreactors is now the norm, and the use of organoids and “organ-on-a-chip” (OoC) is growing, the beginnings of in vitro cell culture were more modest.
Exosomes and extracellular vesicles
Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
Cell and gene therapies
The first edition of our Innovations for Cell and Gene Therapies (ICGT) congress, organized in collaboration with the Société Française de Thérapie Cellulaire et génique (SFTCG), will take place on May 22, 2024, in Paris. In the meantime, this month we share an overview of the cell and gene therapy market.
Advanced therapy medicinal products: from the lab to the patient’s bed
Advanced therapy medicinal products (ATMPs) explore new therapeutic approaches based on genome modification, manipulation of patient or healthy donor cells and other innovative methods, representing a major transition from traditional medicine to more personalized and targeted medicine.
The history of biologics: from discovery to therapeutic revolution
Biopharmaceuticals, or biotherapies, are becoming increasingly important on the market, and offer immense hope for the treatment of many diseases. From the first discoveries of vaccines to the recent development of cell and gene therapies and regenerative medicine, looking back at biologics’ history lets us have a better understanding of the revolution that they provoked in the pharmaceutical industry and in modern medicine .
Therapeutic vaccines in oncology
This month, MabDesign’s market analysis provides an overview of the market for therapeutic oncology vaccines.
antibody-drug conjugates
This month’s MabDesign market analysis gives you an overview of the antibody-drug conjugates market and projects in development.
Neurological disorders
This month’s market analysis by MabDesign gives you an overview of market dynamics and projects in development targeting neurological disorders.